长春瑞滨联合顺铂治疗复发性小细胞肺癌的临床观察

Clinical Observation of Navelbine Combined with Cisplatin in the Treatment of Patients with Recurrence Small Cell Lung Cancer

目的观察长春瑞滨(NVB)联合顺铂(DDP)治疗复发性小细胞肺癌的临床疗效和毒副反应。方法复发性小细胞肺癌44例,接受NVB联合DDP的化疗方案,NVB 25 mg/m2,快速静滴,d1,8给药;DDP 30 mg/m2,静滴,d1-3给药,21 d为1周期。化疗2周期以上,然后按照WHO标准评价临床疗效和毒副反应。结果44例均可评价疗效,获得CR 5例,PR 15例,SD 11例,PD 13例,有效率为45.5%,中位肿瘤进展时间(TTP)为2.5个月。主要毒副反应为骨髓抑制、恶心、呕吐和脱发。结论NVB联合DDP治疗复发性小细胞肺癌的临床疗效较好,毒副反应轻,值得推广应用。

Objective To evaluate the efficacy and toxicity of navelbine combined with cisplatin in the treatment of patients with recurrence small cell lung cancer. Methods 44 patients with recurrence small cell lung cancer were treated with intravenous infusion of navelbine 25 mg/m^2 on dl.8 , cisplatin 30 mg/m^2 on d1 -3 The patients were repeatedly treated every 21 days. The efficacy and toxicity were evaluated by standard of WHO after 2 cycles. Results All the 44 cases were available for objective response, CR 5 cases, PR 15 cases, SD 11 cases and PD 13 cases. The overall response rates and median TTP were 45.5% and 2.5 months. The main toxicities were myelosuppression and nausea/vomiting. Conclusions The combination chemotherapy with navelbine combined with cisplatin in the treatment of patients with recurrence small cell lung cancer is effective and the side effects could be tolerated.